ERAS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ERAS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Erasca does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
The historical data trend for Erasca's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Cyclically Adjusted PB Ratio | - | - | - | - | - |
Erasca Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Erasca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Erasca's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Erasca's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Erasca does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
Erasca (NAS:ERAS) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Erasca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan E Lim | director, 10 percent owner, officer: See Remarks | 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121 |
Start Valerie Denise Harding | director | C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121 |
Alexander W. Casdin | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
Shannon Morris | officer: Chief Medical Officer | C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121 |
James Arthur Bristol | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Cormorant Asset Management, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | director | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Ii, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Jean I Liu | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Pratik S Multani | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Julie Hambleton | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Ebun Garner | officer: General Counsel | C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011 |
Lim Conyee T. | 10 percent owner | C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121 |
Arch Venture Fund X, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 05-16-2023
By Marketwired • 06-22-2023
By Marketwired • 08-10-2023
By Marketwired • 08-29-2023
By Stock market mentor Stock market mentor • 02-01-2023
By sperokesalga sperokesalga • 06-01-2023
By Value_Insider Value_Insider • 12-13-2022
By Value_Insider Value_Insider • 12-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.